A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate

Criteria

Inclusion Criteria:

• Male or Female, > 18 years of age

• Mild to moderate asthma requiring treatment with an inhaled corticosteroid

• Diagnosis of asthma for at least 6 months

Exclusion Criteria:

• Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)

• Subjects with severe asthma, as judged by investigator

• Any significant disease or disorder that may jeopardize a subject's safety